Answers are grounded in this paper and cite their sources.
Background Artemisia pollen is a major cause of seasonal respiratory allergy, yet allergen-specific immunotherapy (AIT) still relies mainly on crude extracts. Art an 3 is a major Artemisia annua pollen allergen, but its therapeutic and immunological features relative to extracts remain unclear. Objective To compare recombinant Art an 3 (rArt an 3)–based versus extract-based subcutaneous immunotherapy (SCIT) in an A. annua pollen–induced murine asthma model. Methods Female BALB/c mice were sensitized and intranasally challenged with A. annua pollen extract, then treated with Extracts-SCIT, rArt an 3-SCIT, or PBS. Airway hyperresponsiveness (AHR), lung histopathology, bronchoalveolar lavage fluid (BALF) cells, splenic cytokines, serum immunoglobulins, and splenic CD4 + T-cell subsets were evaluated. Results Both SCIT regimens reduced peribronchial inflammation, goblet-cell mucus, and methacholine-induced AHR versus positive controls; histologic improvement tended to be greater with Extracts-SCIT, whereas AHR improvement was comparable. Extracts-SCIT more clearly decreased BALF eosinophils and IL-5/IL-17A. rArt an 3-SCIT preferentially increased IL-10 and IFN- γ and enhanced splenic Treg/Th1 responses. Pollen-specific sIgE decreased most with Extracts-SCIT, while rArt an 3-SCIT showed a modest sIgE reduction but a more pronounced increase in pollen-specific sIgG1. Conclusion rArt an 3-SCIT showed overall protection comparable to Extracts-SCIT, with a regulatory/Th1-associated profile characterized by increased Treg/Th1 responses and pollen-specific sIgG1, supporting rArt an 3 as a molecularly defined AIT candidate for Artemisia pollen allergy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: